Quick Answer
NeuroSense Therapeutics Ltd. reported Operating Income of -$11.09 million for fiscal year 2025.
NeuroSense Therapeutics Ltd. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$11.09M | -11.9% |
| 2024 | -$9.90M | +17.8% |
| 2023 | -$12.05M | -14.2% |
| 2022 | -$10.55M | — |
- NeuroSense Therapeutics Ltd. showed a decrease of -11.9% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, NeuroSense Therapeutics Ltd.’s operating income has declined by 5.0% (from -$10.55 million to -$11.09 million).
- The most recent figure is from NeuroSense Therapeutics Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: